(Total Views: 430)
Posted On: 05/14/2025 1:08:16 PM
Post# of 155729
Quote:
Excerpt: OlympiA trial researchers studied 1,836 women with HER-2 negative breast cancer, who also had a mutation in their BRCA1 or BRCA2 genes and had undergone standard treatment, including surgery and chemotherapy. Patients were randomly allocated to receive either 300mg twice a day of olaparib or a placebo drug for one year
Yesterday when I was trying to locate the study showing the downregulation of PD-L1 I ran across a different study that showed the effects of maraviroc on BRCA1- associated protein 1 (BAP1)- mutant clear cell renal cell carcinoma.
Quote:
We demonstrated that BAP1 mutation led to increased expression of CCR5 on Tregs and tumor cells. Application of anti- CCR5 antibody induced the antitumor immune response and effectively inhibited tumor growth. The present study revealed that tumor cells could secrete CCR5 ligands, which could bind with the tumor cell surface receptor and induce increased PD- L1 expression, and recruit CCR5+ Tregs to the local tumor microenvironment and promote immune evasion. CCR5 blockade could prohibited both of these processes and might serve as a potential new therapeutic approach
https://jitc.bmj.com/content/jitc/8/1/e000228.full.pdf
(12)
(0)
